These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

487 related articles for article (PubMed ID: 23200811)

  • 21. The effect of neoadjuvant chemotherapy on perioperative outcomes in patients who have bladder cancer treated with radical cystectomy: a population-based study.
    Gandaglia G; Popa I; Abdollah F; Schiffmann J; Shariat SF; Briganti A; Montorsi F; Trinh QD; Karakiewicz PI; Sun M
    Eur Urol; 2014 Sep; 66(3):561-8. PubMed ID: 24486024
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Low incidence of perioperative chemotherapy for stage III bladder cancer 1998 to 2003: a report from the National Cancer Data Base.
    David KA; Milowsky MI; Ritchey J; Carroll PR; Nanus DM
    J Urol; 2007 Aug; 178(2):451-4. PubMed ID: 17561135
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Management of muscle-invasive bladder cancer in Victoria, 1990-1995.
    Millar JL; Frydenberg M; Toner G; Syme R; Thursfield V; Giles GG;
    ANZ J Surg; 2006 Mar; 76(3):113-9. PubMed ID: 16626343
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Neoadjuvant chemotherapy in patients with muscle-invasive bladder cancer: which patients benefit?
    Niegisch G; Lorch A; Droller MJ; Lavery HJ; Stensland KD; Albers P
    Eur Urol; 2013 Sep; 64(3):355-7. PubMed ID: 23773558
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Trends and appropriateness of perioperative chemotherapy for muscle-invasive bladder cancer.
    Macleod LC; Yabes JG; Yu M; Fam MM; Hale NE; Turner RM; Lopa SH; Gingrich JR; Borza T; Skolarus TA; Davies BJ; Jacobs BL
    Urol Oncol; 2019 Jul; 37(7):462-469. PubMed ID: 31053530
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Long-term outcomes in patients with muscle-invasive bladder cancer after selective bladder-preserving combined-modality therapy: a pooled analysis of Radiation Therapy Oncology Group protocols 8802, 8903, 9506, 9706, 9906, and 0233.
    Mak RH; Hunt D; Shipley WU; Efstathiou JA; Tester WJ; Hagan MP; Kaufman DS; Heney NM; Zietman AL
    J Clin Oncol; 2014 Dec; 32(34):3801-9. PubMed ID: 25366678
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Selective bladder-sparing protocol consisting of induction low-dose chemoradiotherapy plus partial cystectomy with pelvic lymph node dissection against muscle-invasive bladder cancer: oncological outcomes of the initial 46 patients.
    Koga F; Kihara K; Yoshida S; Yokoyama M; Saito K; Masuda H; Fujii Y; Kawakami S
    BJU Int; 2012 Mar; 109(6):860-6. PubMed ID: 21854531
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Concurrent chemotherapy is associated with improved survival in elderly patients with bladder cancer undergoing radiotherapy.
    Korpics MC; Block AM; Martin B; Hentz C; Gaynor ER; Henry E; Harkenrider MM; Solanki AA
    Cancer; 2017 Sep; 123(18):3524-3531. PubMed ID: 28581675
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Accelerated methotrexate, vinblastine, doxorubicin, and cisplatin (AMVAC) as neoadjuvant chemotherapy for patients with muscle-invasive transitional cell carcinoma of the bladder.
    Blick C; Hall P; Pwint T; Al-Terkait F; Crew J; Powles T; Macaulay V; Munro N; Douglas D; Kilbey N; Protheroe A; Chester JD
    Cancer; 2012 Aug; 118(16):3920-7. PubMed ID: 22614698
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Analysis of Intravesical Recurrence After Bladder-preserving Therapy for Muscle-invasive Bladder Cancer.
    Onozawa M; Miyanaga N; Hinotsu S; Miyazaki J; Oikawa T; Kimura T; Takaoka E; Kawai K; Shimazui T; Sakurai H; Nishiyama H; Akaza H
    Jpn J Clin Oncol; 2012 Sep; 42(9):825-30. PubMed ID: 22782963
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A population-based study of patterns of care for muscle-invasive bladder cancer in Sweden.
    Jahnson S; Damm O; Hellsten S; Holmäng S; Liedberg F; Ljungberg B; Malmström PU; Månsson W; Strömberg F; Wijkstöm H
    Scand J Urol Nephrol; 2009; 43(4):271-6. PubMed ID: 19424934
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Neoadjuvant gemcitabine and carboplatin followed by immediate cystectomy may be associated with a survival benefit in patients with clinical T2 bladder cancer.
    Koie T; Ohyama C; Yamamoto H; Imai A; Hatakeyama S; Yoneyama T; Hashimoto Y; Yoneyama T; Tobisawa Y
    Med Oncol; 2014 May; 31(5):949. PubMed ID: 24700028
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long-term results of two prospective bladder-sparing trimodality approaches for invasive bladder cancer: neoadjuvant chemotherapy and concurrent radio-chemotherapy.
    Zapatero A; Martin De Vidales C; Arellano R; Ibañez Y; Bocardo G; Perez M; Rabadan M; García Vicente F; Cruz Conde JA; Olivier C
    Urology; 2012 Nov; 80(5):1056-62. PubMed ID: 22999456
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Treatment Patterns and Overall Survival Outcomes of Octogenarians with Muscle Invasive Cancer of the Bladder: An Analysis of the National Cancer Database.
    Fischer-Valuck BW; Rao YJ; Rudra S; Przybysz D; Germino E; Samson P; Baumann BC; Gay H; Michalski J
    J Urol; 2018 Feb; 199(2):416-423. PubMed ID: 28842247
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evolving progress in oncologic and operative outcomes for esophageal and junctional cancer: lessons from the experience of a high-volume center.
    Reynolds JV; Donohoe CL; McGillycuddy E; Ravi N; O'Toole D; O'Byrne K; Hollywood D
    J Thorac Cardiovasc Surg; 2012 May; 143(5):1130-1137.e1. PubMed ID: 22244551
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Treatment of esophageal cancer based on histology: a surveillance epidemiology and end results analysis.
    Chang DT; Chapman C; Shen J; Su Z; Koong AC
    Am J Clin Oncol; 2009 Aug; 32(4):405-10. PubMed ID: 19415029
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparative Effectiveness of Trimodal Therapy Versus Radical Cystectomy for Localized Muscle-invasive Urothelial Carcinoma of the Bladder.
    Seisen T; Sun M; Lipsitz SR; Abdollah F; Leow JJ; Menon M; Preston MA; Harshman LC; Kibel AS; Nguyen PL; Bellmunt J; Choueiri TK; Trinh QD
    Eur Urol; 2017 Oct; 72(4):483-487. PubMed ID: 28412065
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Local control of muscle-invasive bladder cancer: preoperative radiotherapy and cystectomy versus cystectomy alone.
    Cole CJ; Pollack A; Zagars GK; Dinney CP; Swanson DA; von Eschenbach AC
    Int J Radiat Oncol Biol Phys; 1995 May; 32(2):331-40. PubMed ID: 7751174
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Significance of ERBB2 overexpression in therapeutic resistance and cancer-specific survival in muscle-invasive bladder cancer patients treated with chemoradiation-based selective bladder-sparing approach.
    Inoue M; Koga F; Yoshida S; Tamura T; Fujii Y; Ito E; Kihara K
    Int J Radiat Oncol Biol Phys; 2014 Oct; 90(2):303-11. PubMed ID: 25304790
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy and safety of systemic chemotherapy and intra-arterial chemotherapy with/without radiotherapy for bladder preservation or as neo-adjuvant therapy in patients with muscle-invasive bladder cancer: a single-centre study of 163 patients.
    Miyata Y; Nomata K; Ohba K; Matsuo T; Hayashi N; Sakamoto I; Uetani M; Sakai H
    Eur J Surg Oncol; 2015 Mar; 41(3):361-7. PubMed ID: 25312685
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.